文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

低剂量阿司匹林化学预防林奇综合征患者结直肠腺瘤的随机对照试验方案

Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial.
PubMed 文献 · Trials · 2020-09-04

林奇综合征患者结直肠癌终身风险高达60%,需定期结肠镜监测。AAS-Lynch试验为多中心、双盲、安慰剂对照随机试验,旨在研究每日100或300 mg阿司匹林能否降低75岁以下患者结直肠腺瘤的发生或复发。该方案基于CAPP-2试验的次要分析提示阿司匹林可能降低结直肠癌风险,但需进一步验证。

要点

  • 林奇综合征患者结直肠癌终身风险估计高达60%。
  • 结肠镜监测建议20-25岁以上每2年一次,发现肿瘤后每年一次。
  • AAS-Lynch试验比较每日100或300 mg阿司匹林与安慰剂对结直肠腺瘤发生或复发的影响。

核心结论

  • AAS-Lynch试验旨在确定每日100或300 mg阿司匹林能否降低75岁以下林奇综合征患者结直肠腺瘤的发生或复发。

研究设计与样本

  • 多中心、前瞻性、双盲、安慰剂对照随机对照试验,纳入75岁以下林奇综合征患者,比较每日阿司匹林100或300 mg与安慰剂。
  • 试验注册号ClinicalTrials.gov NCT02813824,2016年6月27日注册,为前瞻性注册。

主要发现

  • CAPP-2试验主要分析显示每日阿司匹林未显著降低林奇综合征患者结直肠癌风险。
  • CAPP-2试验延长随访后的预计划次要分析显示,符合方案分析中阿司匹林组结直肠癌风险显著降低。

关键数值与推荐

  • 林奇综合征患者结直肠癌终身风险估计高达60%。
  • 建议20-25岁以上林奇综合征患者每2年行结肠镜检查,发现结肠肿瘤后每年一次。
  • 流行病学研究显示规律使用低剂量阿司匹林与散发性结肠腺瘤和结直肠癌风险降低20%至30%相关,与家族风险无关。
  • AAS-Lynch试验阿司匹林剂量为每日100 mg或300 mg,对照为安慰剂,研究对象为75岁以下林奇综合征患者。

临床怎么用

  • 对于林奇综合征患者,阿司匹林化学预防的获益尚待AAS-Lynch等试验进一步确认,目前不能替代结肠镜监测。

局限性

  • CAPP-2试验主要分析未显示阿司匹林显著降低结直肠癌风险,仅延长随访后的预计划次要分析提示可能获益。
  • 阿司匹林在林奇综合征患者中的真实效应和临床获益仍需巩固。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lynch syndrome (LS) is the most common cause of inherited colorectal cancer (CRC) and confers a high lifetime risk of CRC estimated to be up to 60%. Colonoscopy is recommended every 2 years in LS patients above the 20-25-year-old age bracket, and every year when colonic neoplasia has been detected. Efficient chemoprevention has the potential to represent a cost-effective intervention in these high-risk patients and could allow a delay in colonoscopy surveillance. Several epidemiological studies have shown that regular use of low dose aspirin is associated with a 20 to 30% reduction in the risk of sporadic colonic adenomas and colorectal cancer regardless of family risk. However, in recent large randomized trials in specific populations, aspirin use showed no protection for colorectal cancer. A prospective randomized CAPP-2 trial evaluated the effect of aspirin use in LS patients. The primary analysis of this trial showed no significant decrease in CRC in LS patients under daily aspirin. However, a preplanned secondary analysis after an extended follow-up showed a significant reduced risk of CRC in the aspirin group in the per-protocol analysis. The real effect and clinical benefit of aspirin are still to be consolidated in this population. The AAS-Lynch trial-a prospective, multicentric, double-blind, placebo-controlled, randomized clinical trial-was designed to investigate if daily aspirin therapy, at a dose of 100 or 300 mg, would decrease the occurrence or recurrence of colorectal adenomas in patients under 75 years of age, compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov NCT02813824 . Registered on 27 June 2016. The trial was prospectively registered.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Soualy A, Deutsch D, Benallaoua M, et al. Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. Trials. 2020. PMID: 32887653. doi:10.1186/s13063-020-04674-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。